Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.53 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.53 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.52 |
| ▸ | NR2E1 | Q9Y466 | 7/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | LDLR | P01130 | 1/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388334 | 0.86 | CSF1R (0.60) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL3389503 | 0.85 | BRAF (0.50) | MAPK14MAP4K2MAP3K7BRAFRAF1 | |
| SCHEMBL3386095 | 0.84 | MAP4K2 (0.63) | MAPK14MAP3K20MAP4K2MAP3K7RAF1 | |
| SCHEMBL4714607 | 0.84 | MAP3K7 (0.39) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL2847430 | 0.81 | MAP4K2 (0.58) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL14572600 | 0.80 | BRAF (0.49) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL3390181 | 0.76 | BRAF (0.41) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL13708186 | 0.75 | MAPK14 (0.59) | MAPK14MAP3K20MAP4K2MAP3K7BRAF | |
| SCHEMBL4482184 | 0.74 | NR2E1 (0.67) | MAPK14MAP3K20MAP4K2MAP3K7RAF1 | |
| SCHEMBL4482180 | 0.74 | NR2E1 (0.67) | MAPK14MAP3K20MAP4K2MAP3K7NR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | claimed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | claimed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | claimed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, FYN, SYK | MAPK14 226/4885MAP3K20 33/4885MAP4K2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.